Skip to content

Comparison Effects Of Different Exercise Approaches On Type 2 DM Women

Comparison Effects Of Blue Prescription Program, Home Exercise Program And Supervised Exercise Approaches On Type 2 Diabetic Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05479435
Enrollment
60
Registered
2022-07-29
Start date
2021-09-01
Completion date
2023-09-30
Last updated
2025-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic diseases with a complex, multifactorial etiology, and is a chronic disease with various clinical and biochemical manifestations. It has been known for a long time that T2DM treatments include medication, diet, and exercise. Exercise can improve blood glucose control, increase insulin sensitivity, respiratory capacity, well-being and cognitive functions, regulate lipid profile, blood pressure, reduce cardiovascular disease risk, abdominal obesity, weight. Although there are many studies in the literature on the effects of exercise in T2DM, there is no consensus on which exercise protocol is more effective. In the studies, the obstacles in front of the diabetic patients' adaptation to exercise; laziness, lack of motivation and energy, embarrassment from family and social environment, lack of support, time constraints, financial problems, lack of space to exercise, fear of hypoglycaemia, pain, stiffness, fatigue, shortness of breath, presence of additional diseases, fear of injury. Blue Prescription (BP) is a model developed to facilitate the participation in physical activity. In traditional home programs, patients are told what to do. The BP approach, on the other hand, involves providing the person with options for physical activity, removing the barriers to activity instead of the classical home exercise program or physical activity counselling, and being in communicate according to the person's preferences during this process. This approach has been developed to facilitate participation in physical activity and to ensure the sustainability of physical activity in individuals with chronic diseases. Philosophy of the approach aims to increase the activity level gradually, improve the quality of life and participation in the activity with motivational interview, continuous support, communication and activity diary, instead of recommending physical activity with classical methods due to the different needs, desires and preferences of people. Studies using the BP in the literature have focused on Multiple Sclerosis and stroke, and no publications on other chronic diseases have been found. The aim of this study is to examine the effects of BP, video-based home exercise and supervised group exercises on HbA1c, physical activity level, functional capacity and other metabolic control variables in primary care women with T2DM.

Interventions

BEHAVIORALBlue Prescription Exercise Program

After the evaluation, participants will receive feedback and physical activity training, along with an explanation of the benefits of exercise, provided in the form of a brochure. They will then be enrolled in the Blue Prescription program, which includes weekly follow-ups for 12 weeks and a re-evaluation at the end of the 12th week. Motivation and support will be offered in accordance with the Blue Prescription philosophy, addressing home exercise programs, physical activity selection, and overcoming obstacles. Participants will be encouraged to determine the most suitable program for themselves and maintain an activity diary. Throughout the study, participants will have the opportunity to communicate with the physiotherapist via various methods such as phone, SMS, or email.

BEHAVIORALVideo Based Home Exercise Program

After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.

BEHAVIORALSupervised Group Exercise Program

DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Participants will engage in exercises with a physiotherapist three days a week for 12 weeks, and the effectiveness of the program will be re-evaluated at the end of the 12th week.

Sponsors

Istanbul Medipol University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Masking description

We will mask only person who will do statistical analysis.

Intervention model description

Randomized control trial with statistic analyst blind

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Between 25-65 years of age 2. Having Type 2 DM for at least 5 years 3. HbA1c value\> 6.5% / Fasting blood glucose\> 126 mg / dl 4. Ability to walk independently 5. Volunteering to participate in research

Exclusion criteria

1. Type 1 DM 2. Using insulin 3. Orthopedic and neurological diseases that prevent exercise 4. Having cardiovascular, pulmonary and systemic diseases in which exercise is contraindicated.

Design outcomes

Primary

MeasureTime frameDescription
Heart RateIn the beginning of the intervention and at the end of the exercise program (12 weeks).It is the value that shows how many times the heart beats in a minute. Measurement from the wrist: measured from the radial artery with 3 fingers with the palm facing up. The reference range is between 60 and 100 beats per minute (bpm).
Glycosylated Hemoglobin ChangeChange from Baseline Glycosylated Hemoglobin at 12 weeks.Hemoglobin A1c is a blood test used to measure the effectiveness of treatment in diabetes, and sometimes to diagnose diabetes. The generally accepted reference range for Hemoglobin A1c (HbA1c) is between 4% and 6%.
Physical Activity Level ChangeIn the beginning of the intervention and at the end of the exercise program (12 weeks)The questionnaire provides information about the time spent by the individual in light, moderate, and vigorous activities and sitting in the last 7 days. The MET-min / week score is obtained by multiplying the MET value (metabolic equivalent) by days and minutes for each activity level. Physical activity levels are classified as: Physically inactive (\<600 MET-min / week), Low physical activity (600-3000 MET-min / week), and Adequate physical activity (\> 3000 MET-min / week). A higher score is associated with a higher physical activity level.
Functional Capacity Change With Timed Up And Go TestIn the beginning of the intervention and at the end of the exercise program (12 weeks)The participant will sit on a chair without armrests, stand up with the command to start, walk 3 meters towards the designated point, turn around and walk to the starting point again and sit. The test is repeated 3 times and the average is taken. The time will be recorded in seconds. As time increases, the risk of falling increases.
Functional Capacity Change With 6-minute Walking TestChange from Baseline 6-minute Walking Test Results at 12 weeks.It will be performed in a 30 meter long corridor or in an open area. The participant will be asked to walk without running at the highest speed for 6 minutes. Before and during the march, the participant will be verbally encouraged and motivated. How many meters they walked will be recorded as a result of the test. Six-minute walk test results can be interpreted as follows: Normal: more than 500 meters Light restriction: 400 to 500 meters Moderate restriction: 300 to 400 meters Severe restriction: between 200 - 300 meters Serious restriction: less than 200 meters.
Fasting Plasma GlucoseIn the beginning of the intervention and at the end of the exercise program (12 weeks).Measured level of glucose in the blood after 8 to 12 hours of fasting. The unit of measurement is mg/dL, the reference range is 70-110 mg/dL.
High Density LipoproteinIn the beginning of the intervention and at the end of the exercise program (12 weeks).It takes part in the transport of cholesterol from tissues and vessels to the liver and in the synthesis of vitamin D. The unit of measurement is mg/dL, the reference range is 30-96 mg/dL.
Low Density LipoproteinIn the beginning of the intervention and at the end of the exercise program (12 weeks).It provides the transport of cholesterol synthesized in the liver to the tissues and blood vessels. The unit of measurement is mg/dL, the reference range is 0- 130 mg/dL.
Total CholesterolIn the beginning of the intervention and at the end of the exercise program (12 weeks).Total cholesterol is a value that shows the total amount of cholesterol in the blood. In addition to LDL and HDL, triglyceride levels are also used to calculate total cholesterol. The unit of measurement is mg/dL, the reference range is 70-200 mg/dL.
TriglycerideIn the beginning of the intervention and at the end of the exercise program (12 weeks).It is a storage nutrient molecule formed by the combination of fatty acids and glycerol molecules, which form the structure of fats in foods. The unit of measurement is mg/dL, the reference range is 0-250 mg/dL.
C-reactive ProteinIn the beginning of the intervention and at the end of the exercise program (12 weeks).It is a protein produced in the liver. It is a protein that is produced by cells and secreted into the blood when the body reacts to conditions such as infection, tumor, trauma, and undertakes various biochemical tasks. The unit of measurement is mg/dL, the reference range is 0-0.5 mg/dL.
Systolic Blood PressureIn the beginning of the intervention and at the end of the exercise program (12 weeks).Blood pressure is the pressure that builds up in the blood vessels when the heart contracts. It is measured with a sphygmomanometer. The cuff is placed 2.5 to 3 cm above the inside of the elbow. The stethoscope is placed under the cuff and pressed lightly. The sphygmomanometer cuff is then inflated to 20 to 30 mmHg above the level at which the pulse disappears. The control valve should be opened slightly, and air should be vented at a rate of 2-4 mmHg per second. The first sound heard as the air is released determines the systolic blood pressure. The reference range averages 120 - 130 mmHg.
Diastolic Blood PressureIn the beginning of the intervention and at the end of the exercise program (12 weeks).The pressure that builds up in the blood vessels as the heart relaxes is known as diastolic blood pressure. It is measured using a sphygmomanometer, which is placed 2.5 to 3 cm above the inside of the elbow. The stethoscope is placed under the cuff and lightly pressed. The sphygmomanometer cuff is then inflated to 20 to 30 mmHg above the point where the pulse disappears. The control valve should be opened slightly, and air should be released at a rate of 2-4 mmHg per second. The point at which the sound becomes inaudible is considered the diastolic blood pressure. The reference range averages 70 - 90 mmHg.

Secondary

MeasureTime frameDescription
HeightIn the beginning of the interventionIt will be measured with a stadiometer. Head, shoulders, back, hips, calves and heels will touch the stadiometer, stand upright with feet shoulder-width apart, slide of height meter will be pulled down.
Body Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)Change from Baseline Bioelectrical Impedance Analysis at 12 weeks.-Bioelectrical Impedance Analysis (BIA): The basic principle is to measure the impedance by using the resistance and conductivity that a very small amount of electrical current encounters when passing through tissues. Reference values for Bioelectrical Impedance Analysis (BIA) may vary depending on factors such as age, gender, height and weight. However, a typical BIA reference range for generally healthy adults is as follows: Body Fat Percentage: For women: 20% - 25% Body Mass Index (BMI): Normal Range: 18.5 - 24.9 kg/m² However, these values can vary greatly between individuals and may vary depending on many factors such as clinical conditions, lifestyle factors, ethnicity, etc. Therefore, BIA results should be interpreted taking into account the individual's personal health status and goals. Tanita SC-330 brand device will be used in our study.
Body Fat Ratio Change With Skinfold AnalysisChange from Baseline Skinfold Analysis at 12 weeks.All measurements will be made on the right side of the body. The caliper will be placed approximately 1 cm from the thumb and index finger, and 1-2 seconds will be waited before the caliper is read. Body fat percentages of individuals will be calculated using Jackson-Pollock 7 region equations; Triceps, Subscapularis, Midaxillary, Abdominal, Chest, Suprailiac. The Jackson-Pollock skinfold thickness method is a method used to estimate body fat percentage. Reference values may vary depending on factors such as the person's gender, age range and lifestyle. However, in general, reference values for body fat percentage obtained using the Jackson-Pollock formula are as follows: Athletic women: 14-20% Women in good shape: 21-24% Average women: 25-31% Overweight women: 32-39% Obese women: 40% and above
Flexibility Change With Fingertip-to-floor Distance MeasureChange from Baseline Fingertip-to-floor Distance Measure at 12 weeks.During the test, the participant will be asked to lean forward without bending their knees and try to touch the fingertip. The distance between the tip of the third finger of the hand and the ground will be measured and the result will be recorded in cm. This distance is considered normal up to 0 cm in women and up to 10 cm in men.
Flexibility Change With Trunk Lateral Flexion MeasureChange from Baseline Trunk Lateral Flexion Measure at 12 weeks.The participant will be asked to stand with their feet slightly open, parallel to each other, arms next to the trunk. Mark the distal end of the third finger of the hand on the thigh, and the participant will be asked to perform lateral flexion. The point where the distal of the third finger comes from is marked again. The distance between the two points is cm. will be recorded in terms. A higher value is associated with good flexibility.
Life QualityIn the beginning of the intervention and at the end of the exercise program (12 weeks).The Diabetes Quality of Life (DQoL) Questionnaire consists of 46 items divided into four subscales: Satisfaction (15 items), Impact (20 items), Worry - Social/Vocational (7 items), and Worry - Diabetes-Related (4 items). Each item is rated on a 5-point Likert scale ranging from 1 to 5. Depending on the item, higher scores may indicate either greater dissatisfaction, greater impact, or higher worry. Subscale scores are calculated by summing item responses within each subscale. The total score is the sum of all items and ranges from 46 to 230. Higher total scores indicate a lower diabetes-related quality of life.
DepressionIn the beginning of the intervention and at the end of the exercise program (12 weeks).It will be evaluated with the Beck Depression Scale. The scale is used to measure the level of depression with a 21-item multiple-choice question. Each question is evaluated within a certain score range, and the total score shows the person's depression level. However, the scale does not have an official reference range because scoring may vary depending on clinical or research purposes. In general, Beck Depression Inventory (BDI) scores can be interpreted as follows: 0-13 points: Mild or minimal depression 14-19 points: Mild depression 20-28 points: Moderate depression 29-63 points: Severe depression
ContentmentIn the beginning of the intervention and at the end of the exercise program (12 weeks).It will be evaluated with The Diabetes Treatment Satisfaction Questionnaire (DTSQ). The questionnaire measures how the individual perceives glycemic control and satisfaction with the treatment. Suitable for Type 1 DM and Type 2 DM. It consists of 8 items and is scored on a 0-6 Likert scale. 6 items 1, 4, 5, 6, 7, 8); It meets to determine satisfaction between 0 (not at all) and 6 (very satisfied). Of the remaining items, 2, 0 (never) to 6 almost always) measure the frequency of detection of hyperglycemia, and item 3 measures the frequency of detecting hypoglycemia. The highest score is calculated as 36. High scores indicate satisfaction with treatment, while low scores indicate dissatisfaction.
WeightIn the beginning of the intervention and at the end of the exercise program (12 weeks).It will be measured with a standard weighing instrument.
Neck CircumferenceIn the beginning of the intervention and at the end of the exercise program (12 weeks).In the anatomical position, the tape measure is measured just below the thyroid cartilage.
Waist CircumferenceIn the beginning of the intervention and at the end of the exercise program (12 weeks).It is measured at the thinnest point between the lowest rib and anterior superior to the processus spina ilica in the anatomical position.
Hip CircumferenceIn the beginning of the intervention and at the end of the exercise program (12 weeks).Measured at the widest point of the Gluteus Maximus muscle in the anatomical position
Body Mass Index (BMI)In the beginning of the intervention and at the end of the exercise program (12 weeks).BMI will be calculated by dividing body weight (kg) by height square (m\^2). General reference ranges for BMI are as follows: If BMI is less than 18.5 kg/m\^2: Underweight If BMI is between 18.5-24.9 kg/m\^2: Normal weight If BMI is between 25.0-29.9 kg/m\^2: Overweight If BMI is 30.0 kg/m\^2 and above: Obese

Countries

Turkey (Türkiye)

Participant flow

Recruitment details

September 1st 2021 started day. The study location was Balikesir Provincial Health Directorate, Edremit District Health Directorates Healthy Life Center, Balikesir, Turkey.

Pre-assignment details

The participiants who diagnosed with Diabetes Mellitus Type 2, were recruited from Balikesir Provincial Health Directorate, Edremit District Health Directorates Healthy Life Center. They were 60 people who were assigned to the groups.

Participants by arm

ArmCount
Blue Prescription Group
Participants will get an exercise program, which is designed by their needs, desires and abilities. They will perform a desired exercise program 3 days a week and they will make an interview for motivation and/or modifying the program one day a week. They will write an activity diary. Blue Prescription Exercise Program: After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).
20
Video Based Home Exercise Group
Participants will get videos by different ways (closed link youtube, whatsapp, flash driver etc.). They will perform exercises 3 days a week. İnvestigator will phone them to ask whether they do the program or not. They will write an activity diary. Video Based Home Exercise Program: After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
20
Supervised Exercise Group
Participants will perform an exercise program 3 days a week with a physiotherapist. The group will be held maximum 10 people. Supervised Group Exercise Program: DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
20
Total60

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyCovid 19002
Overall StudyWithdrawal by Subject100

Baseline characteristics

CharacteristicVideo Based Home Exercise GroupSupervised Exercise GroupTotalBlue Prescription Group
Age, Continuous48.85 years
STANDARD_DEVIATION 8.79
50.39 years
STANDARD_DEVIATION 8.46
50.61 years
STANDARD_DEVIATION 8.77
52.68 years
STANDARD_DEVIATION 9.08
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Turkey
20 Participants20 Participants60 Participants20 Participants
Sex: Female, Male
Female
20 Participants20 Participants60 Participants20 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 200 / 20
other
Total, other adverse events
0 / 200 / 200 / 20
serious
Total, serious adverse events
0 / 200 / 200 / 20

Outcome results

Primary

C-reactive Protein

It is a protein produced in the liver. It is a protein that is produced by cells and secreted into the blood when the body reacts to conditions such as infection, tumor, trauma, and undertakes various biochemical tasks. The unit of measurement is mg/dL, the reference range is 0-0.5 mg/dL.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupC-reactive Proteinbaseline2.31 mg/dLStandard Deviation 3.63
Blue Prescription GroupC-reactive Proteinat the end of the 12 weeks1.83 mg/dLStandard Deviation 2.95
Video Based Home Exercise GroupC-reactive Proteinbaseline1.55 mg/dLStandard Deviation 1.25
Video Based Home Exercise GroupC-reactive Proteinat the end of the 12 weeks1.51 mg/dLStandard Deviation 1.03
Supervised Exercise GroupC-reactive Proteinat the end of the 12 weeks2.46 mg/dLStandard Deviation 2.55
Supervised Exercise GroupC-reactive Proteinbaseline3.51 mg/dLStandard Deviation 4.12
p-value: 0.504Kruskal-Wallis
Primary

Diastolic Blood Pressure

The pressure that builds up in the blood vessels as the heart relaxes is known as diastolic blood pressure. It is measured using a sphygmomanometer, which is placed 2.5 to 3 cm above the inside of the elbow. The stethoscope is placed under the cuff and lightly pressed. The sphygmomanometer cuff is then inflated to 20 to 30 mmHg above the point where the pulse disappears. The control valve should be opened slightly, and air should be released at a rate of 2-4 mmHg per second. The point at which the sound becomes inaudible is considered the diastolic blood pressure. The reference range averages 70 - 90 mmHg.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupDiastolic Blood Pressurebaseline77.05 mmHgStandard Deviation 8.08
Blue Prescription GroupDiastolic Blood Pressureat the end of the 12 weeks75.47 mmHgStandard Deviation 7.24
Video Based Home Exercise GroupDiastolic Blood Pressurebaseline80.10 mmHgStandard Deviation 6.16
Video Based Home Exercise GroupDiastolic Blood Pressureat the end of the 12 weeks78.85 mmHgStandard Deviation 6.01
Supervised Exercise GroupDiastolic Blood Pressurebaseline83.50 mmHgStandard Deviation 6.72
Supervised Exercise GroupDiastolic Blood Pressureat the end of the 12 weeks81.39 mmHgStandard Deviation 6.43
p-value: 0.025Kruskal-Wallis
Primary

Fasting Plasma Glucose

Measured level of glucose in the blood after 8 to 12 hours of fasting. The unit of measurement is mg/dL, the reference range is 70-110 mg/dL.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupFasting Plasma Glucosebaseline138.21 (mg/dL)Standard Deviation 34.49
Blue Prescription GroupFasting Plasma Glucoseat the end of the 12 weeks115.53 (mg/dL)Standard Deviation 22.48
Video Based Home Exercise GroupFasting Plasma Glucosebaseline157.05 (mg/dL)Standard Deviation 60.9
Video Based Home Exercise GroupFasting Plasma Glucoseat the end of the 12 weeks145.50 (mg/dL)Standard Deviation 43.73
Supervised Exercise GroupFasting Plasma Glucosebaseline128.33 (mg/dL)Standard Deviation 25.02
Supervised Exercise GroupFasting Plasma Glucoseat the end of the 12 weeks118.28 (mg/dL)Standard Deviation 20.57
p-value: 0.132Kruskal-Wallis
Primary

Functional Capacity Change With 6-minute Walking Test

It will be performed in a 30 meter long corridor or in an open area. The participant will be asked to walk without running at the highest speed for 6 minutes. Before and during the march, the participant will be verbally encouraged and motivated. How many meters they walked will be recorded as a result of the test. Six-minute walk test results can be interpreted as follows: Normal: more than 500 meters Light restriction: 400 to 500 meters Moderate restriction: 300 to 400 meters Severe restriction: between 200 - 300 meters Serious restriction: less than 200 meters.

Time frame: Change from Baseline 6-minute Walking Test Results at 12 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupFunctional Capacity Change With 6-minute Walking Testat the end of the 12 weeks462.82 meterStandard Deviation 44.38
Blue Prescription GroupFunctional Capacity Change With 6-minute Walking Testbaseline402.57 meterStandard Deviation 38.52
Video Based Home Exercise GroupFunctional Capacity Change With 6-minute Walking Testbaseline405.95 meterStandard Deviation 44.84
Video Based Home Exercise GroupFunctional Capacity Change With 6-minute Walking Testat the end of the 12 weeks457.85 meterStandard Deviation 55.35
Supervised Exercise GroupFunctional Capacity Change With 6-minute Walking Testbaseline416.97 meterStandard Deviation 49.66
Supervised Exercise GroupFunctional Capacity Change With 6-minute Walking Testat the end of the 12 weeks483.44 meterStandard Deviation 55.32
p-value: 0.398ANCOVA
Primary

Functional Capacity Change With Timed Up And Go Test

The participant will sit on a chair without armrests, stand up with the command to start, walk 3 meters towards the designated point, turn around and walk to the starting point again and sit. The test is repeated 3 times and the average is taken. The time will be recorded in seconds. As time increases, the risk of falling increases.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks)

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupFunctional Capacity Change With Timed Up And Go Testbaseline10.64 secondStandard Deviation 1.8
Blue Prescription GroupFunctional Capacity Change With Timed Up And Go Testat the end of the 12 weeks9.21 secondStandard Deviation 1.29
Video Based Home Exercise GroupFunctional Capacity Change With Timed Up And Go Testbaseline10.31 secondStandard Deviation 1.74
Video Based Home Exercise GroupFunctional Capacity Change With Timed Up And Go Testat the end of the 12 weeks8.99 secondStandard Deviation 1.51
Supervised Exercise GroupFunctional Capacity Change With Timed Up And Go Testbaseline10.62 secondStandard Deviation 1.71
Supervised Exercise GroupFunctional Capacity Change With Timed Up And Go Testat the end of the 12 weeks9.26 secondStandard Deviation 1.37
p-value: 0.803ANCOVA
Primary

Glycosylated Hemoglobin Change

Hemoglobin A1c is a blood test used to measure the effectiveness of treatment in diabetes, and sometimes to diagnose diabetes. The generally accepted reference range for Hemoglobin A1c (HbA1c) is between 4% and 6%.

Time frame: Change from Baseline Glycosylated Hemoglobin at 12 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupGlycosylated Hemoglobin ChangeBaseline6.82 percentage of glycosylated hemoglobinStandard Deviation 1.21
Blue Prescription GroupGlycosylated Hemoglobin ChangeAt the end of 12 weeks6.33 percentage of glycosylated hemoglobinStandard Deviation 0.94
Video Based Home Exercise GroupGlycosylated Hemoglobin ChangeBaseline7.17 percentage of glycosylated hemoglobinStandard Deviation 2.37
Video Based Home Exercise GroupGlycosylated Hemoglobin ChangeAt the end of 12 weeks6.69 percentage of glycosylated hemoglobinStandard Deviation 2.08
Supervised Exercise GroupGlycosylated Hemoglobin ChangeBaseline6.80 percentage of glycosylated hemoglobinStandard Deviation 0.94
Supervised Exercise GroupGlycosylated Hemoglobin ChangeAt the end of 12 weeks6.32 percentage of glycosylated hemoglobinStandard Deviation 0.91
p-value: 0.83Kruskal-Wallis
Primary

Heart Rate

It is the value that shows how many times the heart beats in a minute. Measurement from the wrist: measured from the radial artery with 3 fingers with the palm facing up. The reference range is between 60 and 100 beats per minute (bpm).

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupHeart Ratebaseline72.63 beats/minStandard Deviation 7.3
Blue Prescription GroupHeart Rateat the end of the 12 weeks71.16 beats/minStandard Deviation 6.1
Video Based Home Exercise GroupHeart Ratebaseline73.70 beats/minStandard Deviation 6.28
Video Based Home Exercise GroupHeart Rateat the end of the 12 weeks72.30 beats/minStandard Deviation 5.11
Supervised Exercise GroupHeart Ratebaseline76.56 beats/minStandard Deviation 5.55
Supervised Exercise GroupHeart Rateat the end of the 12 weeks74.11 beats/minStandard Deviation 4.2
p-value: 0.016ANCOVA
Primary

High Density Lipoprotein

It takes part in the transport of cholesterol from tissues and vessels to the liver and in the synthesis of vitamin D. The unit of measurement is mg/dL, the reference range is 30-96 mg/dL.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupHigh Density Lipoproteinbaseline52.74 mg/dLStandard Deviation 11.11
Blue Prescription GroupHigh Density Lipoproteinat the end of the 12 weeks59.05 mg/dLStandard Deviation 11.26
Video Based Home Exercise GroupHigh Density Lipoproteinbaseline54.30 mg/dLStandard Deviation 10.31
Video Based Home Exercise GroupHigh Density Lipoproteinat the end of the 12 weeks59.20 mg/dLStandard Deviation 10.5
Supervised Exercise GroupHigh Density Lipoproteinbaseline54.83 mg/dLStandard Deviation 20.8
Supervised Exercise GroupHigh Density Lipoproteinat the end of the 12 weeks62.53 mg/dLStandard Deviation 19.23
p-value: 0.991Kruskal-Wallis
Primary

Low Density Lipoprotein

It provides the transport of cholesterol synthesized in the liver to the tissues and blood vessels. The unit of measurement is mg/dL, the reference range is 0- 130 mg/dL.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupLow Density Lipoproteinbaseline136.58 mg/dLStandard Deviation 33.62
Blue Prescription GroupLow Density Lipoproteinat the end of the 12 weeks125.37 mg/dLStandard Deviation 31.55
Video Based Home Exercise GroupLow Density Lipoproteinbaseline123.45 mg/dLStandard Deviation 24.57
Video Based Home Exercise GroupLow Density Lipoproteinat the end of the 12 weeks116.90 mg/dLStandard Deviation 20.79
Supervised Exercise GroupLow Density Lipoproteinbaseline156.00 mg/dLStandard Deviation 67.9
Supervised Exercise GroupLow Density Lipoproteinat the end of the 12 weeks130.33 mg/dLStandard Deviation 39.47
p-value: 0.278Kruskal-Wallis
Primary

Physical Activity Level Change

The questionnaire provides information about the time spent by the individual in light, moderate, and vigorous activities and sitting in the last 7 days. The MET-min / week score is obtained by multiplying the MET value (metabolic equivalent) by days and minutes for each activity level. Physical activity levels are classified as: Physically inactive (\<600 MET-min / week), Low physical activity (600-3000 MET-min / week), and Adequate physical activity (\> 3000 MET-min / week). A higher score is associated with a higher physical activity level.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks)

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupPhysical Activity Level Changebaseline846.45 MET-min / weekStandard Deviation 615.04
Blue Prescription GroupPhysical Activity Level Changeat the end of the 12 weeks1960.89 MET-min / weekStandard Deviation 735.78
Video Based Home Exercise GroupPhysical Activity Level Changebaseline797.20 MET-min / weekStandard Deviation 635.14
Video Based Home Exercise GroupPhysical Activity Level Changeat the end of the 12 weeks1654.05 MET-min / weekStandard Deviation 770.22
Supervised Exercise GroupPhysical Activity Level Changebaseline909.64 MET-min / weekStandard Deviation 699.9
Supervised Exercise GroupPhysical Activity Level Changeat the end of the 12 weeks2370.11 MET-min / weekStandard Deviation 772.45
p-value: 0.654ANCOVA
Primary

Systolic Blood Pressure

Blood pressure is the pressure that builds up in the blood vessels when the heart contracts. It is measured with a sphygmomanometer. The cuff is placed 2.5 to 3 cm above the inside of the elbow. The stethoscope is placed under the cuff and pressed lightly. The sphygmomanometer cuff is then inflated to 20 to 30 mmHg above the level at which the pulse disappears. The control valve should be opened slightly, and air should be vented at a rate of 2-4 mmHg per second. The first sound heard as the air is released determines the systolic blood pressure. The reference range averages 120 - 130 mmHg.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupSystolic Blood Pressurebaseline128.63 mmHgStandard Deviation 8.32
Blue Prescription GroupSystolic Blood Pressureat the end of the 12 weeks123.63 mmHgStandard Deviation 7.82
Video Based Home Exercise GroupSystolic Blood Pressurebaseline129.05 mmHgStandard Deviation 8.25
Video Based Home Exercise GroupSystolic Blood Pressureat the end of the 12 weeks126.30 mmHgStandard Deviation 7.76
Supervised Exercise GroupSystolic Blood Pressurebaseline134.78 mmHgStandard Deviation 7.8
Supervised Exercise GroupSystolic Blood Pressureat the end of the 12 weeks129.17 mmHgStandard Deviation 6.4
p-value: 0.017ANCOVA
Primary

Total Cholesterol

Total cholesterol is a value that shows the total amount of cholesterol in the blood. In addition to LDL and HDL, triglyceride levels are also used to calculate total cholesterol. The unit of measurement is mg/dL, the reference range is 70-200 mg/dL.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupTotal Cholesterolbaseline219.21 mg/dLStandard Deviation 46.28
Blue Prescription GroupTotal Cholesterolat the end of the 12 weeks203.00 mg/dLStandard Deviation 43.61
Video Based Home Exercise GroupTotal Cholesterolbaseline208.40 mg/dLStandard Deviation 33.36
Video Based Home Exercise GroupTotal Cholesterolat the end of the 12 weeks189.90 mg/dLStandard Deviation 28.55
Supervised Exercise GroupTotal Cholesterolbaseline221.28 mg/dLStandard Deviation 31.84
Supervised Exercise GroupTotal Cholesterolat the end of the 12 weeks200.61 mg/dLStandard Deviation 27.89
p-value: 0.479ANCOVA
Primary

Triglyceride

It is a storage nutrient molecule formed by the combination of fatty acids and glycerol molecules, which form the structure of fats in foods. The unit of measurement is mg/dL, the reference range is 0-250 mg/dL.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupTriglyceridebaseline173.16 mg/dLStandard Deviation 58.5
Blue Prescription GroupTriglycerideat the end of the 12 weeks156.00 mg/dLStandard Deviation 54.29
Video Based Home Exercise GroupTriglyceridebaseline172.15 mg/dLStandard Deviation 36.08
Video Based Home Exercise GroupTriglycerideat the end of the 12 weeks152.85 mg/dLStandard Deviation 38.48
Supervised Exercise GroupTriglyceridebaseline203.12 mg/dLStandard Deviation 139.64
Supervised Exercise GroupTriglycerideat the end of the 12 weeks184.22 mg/dLStandard Deviation 109.6
p-value: 0.849Kruskal-Wallis
Secondary

Body Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)

-Bioelectrical Impedance Analysis (BIA): The basic principle is to measure the impedance by using the resistance and conductivity that a very small amount of electrical current encounters when passing through tissues. Reference values for Bioelectrical Impedance Analysis (BIA) may vary depending on factors such as age, gender, height and weight. However, a typical BIA reference range for generally healthy adults is as follows: Body Fat Percentage: For women: 20% - 25% Body Mass Index (BMI): Normal Range: 18.5 - 24.9 kg/m² However, these values can vary greatly between individuals and may vary depending on many factors such as clinical conditions, lifestyle factors, ethnicity, etc. Therefore, BIA results should be interpreted taking into account the individual's personal health status and goals. Tanita SC-330 brand device will be used in our study.

Time frame: Change from Baseline Bioelectrical Impedance Analysis at 12 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupBody Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)baseline43.63 percent body fatStandard Deviation 4.86
Blue Prescription GroupBody Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)at the end of the 12 weeks41.79 percent body fatStandard Deviation 5.04
Video Based Home Exercise GroupBody Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)baseline40.27 percent body fatStandard Deviation 4.53
Video Based Home Exercise GroupBody Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)at the end of the 12 weeks38.30 percent body fatStandard Deviation 4.77
Supervised Exercise GroupBody Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)baseline43.54 percent body fatStandard Deviation 4.04
Supervised Exercise GroupBody Fat Ratio Change With Bioelectrical Impedance Analysis (BIA)at the end of the 12 weeks41.06 percent body fatStandard Deviation 4.15
p-value: 0.041ANCOVA
Secondary

Body Fat Ratio Change With Skinfold Analysis

All measurements will be made on the right side of the body. The caliper will be placed approximately 1 cm from the thumb and index finger, and 1-2 seconds will be waited before the caliper is read. Body fat percentages of individuals will be calculated using Jackson-Pollock 7 region equations; Triceps, Subscapularis, Midaxillary, Abdominal, Chest, Suprailiac. The Jackson-Pollock skinfold thickness method is a method used to estimate body fat percentage. Reference values may vary depending on factors such as the person's gender, age range and lifestyle. However, in general, reference values for body fat percentage obtained using the Jackson-Pollock formula are as follows: Athletic women: 14-20% Women in good shape: 21-24% Average women: 25-31% Overweight women: 32-39% Obese women: 40% and above

Time frame: Change from Baseline Skinfold Analysis at 12 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupBody Fat Ratio Change With Skinfold Analysisbaseline42.76 percent body fatStandard Deviation 3.04
Blue Prescription GroupBody Fat Ratio Change With Skinfold Analysisat the end of the 12 weeks41.85 percent body fatStandard Deviation 3.19
Video Based Home Exercise GroupBody Fat Ratio Change With Skinfold Analysisbaseline41.59 percent body fatStandard Deviation 3.39
Video Based Home Exercise GroupBody Fat Ratio Change With Skinfold Analysisat the end of the 12 weeks40.78 percent body fatStandard Deviation 3.36
Supervised Exercise GroupBody Fat Ratio Change With Skinfold Analysisbaseline43.36 percent body fatStandard Deviation 1.95
Supervised Exercise GroupBody Fat Ratio Change With Skinfold Analysisat the end of the 12 weeks42.55 percent body fatStandard Deviation 2.1
p-value: 0.352Kruskal-Wallis
Secondary

Body Mass Index (BMI)

BMI will be calculated by dividing body weight (kg) by height square (m\^2). General reference ranges for BMI are as follows: If BMI is less than 18.5 kg/m\^2: Underweight If BMI is between 18.5-24.9 kg/m\^2: Normal weight If BMI is between 25.0-29.9 kg/m\^2: Overweight If BMI is 30.0 kg/m\^2 and above: Obese

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupBody Mass Index (BMI)baseline35.93 kg/m^2Standard Deviation 5.73
Blue Prescription GroupBody Mass Index (BMI)at the end of the 12 weeks34.36 kg/m^2Standard Deviation 4.95
Video Based Home Exercise GroupBody Mass Index (BMI)baseline32.04 kg/m^2Standard Deviation 5.04
Video Based Home Exercise GroupBody Mass Index (BMI)at the end of the 12 weeks31.24 kg/m^2Standard Deviation 4.74
Supervised Exercise GroupBody Mass Index (BMI)baseline34.76 kg/m^2Standard Deviation 5.03
Supervised Exercise GroupBody Mass Index (BMI)at the end of the 12 weeks32.32 kg/m^2Standard Deviation 4.53
p-value: 0.055ANCOVA
Secondary

Contentment

It will be evaluated with The Diabetes Treatment Satisfaction Questionnaire (DTSQ). The questionnaire measures how the individual perceives glycemic control and satisfaction with the treatment. Suitable for Type 1 DM and Type 2 DM. It consists of 8 items and is scored on a 0-6 Likert scale. 6 items 1, 4, 5, 6, 7, 8); It meets to determine satisfaction between 0 (not at all) and 6 (very satisfied). Of the remaining items, 2, 0 (never) to 6 almost always) measure the frequency of detection of hyperglycemia, and item 3 measures the frequency of detecting hypoglycemia. The highest score is calculated as 36. High scores indicate satisfaction with treatment, while low scores indicate dissatisfaction.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupContentmentbaseline21.37 units on a scaleStandard Deviation 4.03
Blue Prescription GroupContentmentat the end of the 12 weeks29.63 units on a scaleStandard Deviation 2.03
Video Based Home Exercise GroupContentmentbaseline22.30 units on a scaleStandard Deviation 4.73
Video Based Home Exercise GroupContentmentat the end of the 12 weeks29.75 units on a scaleStandard Deviation 2.65
Supervised Exercise GroupContentmentbaseline19.28 units on a scaleStandard Deviation 4.9
Supervised Exercise GroupContentmentat the end of the 12 weeks32.17 units on a scaleStandard Deviation 1.58
p-value: 0.367Kruskal-Wallis
Secondary

Depression

It will be evaluated with the Beck Depression Scale. The scale is used to measure the level of depression with a 21-item multiple-choice question. Each question is evaluated within a certain score range, and the total score shows the person's depression level. However, the scale does not have an official reference range because scoring may vary depending on clinical or research purposes. In general, Beck Depression Inventory (BDI) scores can be interpreted as follows: 0-13 points: Mild or minimal depression 14-19 points: Mild depression 20-28 points: Moderate depression 29-63 points: Severe depression

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupDepressionbaseline12.95 units on a scaleStandard Deviation 7.42
Blue Prescription GroupDepressionat the end of the 12weeks9.37 units on a scaleStandard Deviation 5.24
Video Based Home Exercise GroupDepressionat the end of the 12weeks9.65 units on a scaleStandard Deviation 4.13
Video Based Home Exercise GroupDepressionbaseline13.15 units on a scaleStandard Deviation 4.66
Supervised Exercise GroupDepressionbaseline16.17 units on a scaleStandard Deviation 5.22
Supervised Exercise GroupDepressionat the end of the 12weeks9.78 units on a scaleStandard Deviation 4.41
p-value: 0.133Kruskal-Wallis
Secondary

Flexibility Change With Fingertip-to-floor Distance Measure

During the test, the participant will be asked to lean forward without bending their knees and try to touch the fingertip. The distance between the tip of the third finger of the hand and the ground will be measured and the result will be recorded in cm. This distance is considered normal up to 0 cm in women and up to 10 cm in men.

Time frame: Change from Baseline Fingertip-to-floor Distance Measure at 12 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupFlexibility Change With Fingertip-to-floor Distance Measurebaseline9.05 centimeterStandard Deviation 4.08
Blue Prescription GroupFlexibility Change With Fingertip-to-floor Distance Measureat the end of the 12 weeks4.16 centimeterStandard Deviation 4.51
Video Based Home Exercise GroupFlexibility Change With Fingertip-to-floor Distance Measurebaseline10.90 centimeterStandard Deviation 8.9
Video Based Home Exercise GroupFlexibility Change With Fingertip-to-floor Distance Measureat the end of the 12 weeks7.70 centimeterStandard Deviation 7.23
Supervised Exercise GroupFlexibility Change With Fingertip-to-floor Distance Measurebaseline9.67 centimeterStandard Deviation 5.79
Supervised Exercise GroupFlexibility Change With Fingertip-to-floor Distance Measureat the end of the 12 weeks5.67 centimeterStandard Deviation 4.28
p-value: 0.39Kruskal-Wallis
Secondary

Flexibility Change With Trunk Lateral Flexion Measure

The participant will be asked to stand with their feet slightly open, parallel to each other, arms next to the trunk. Mark the distal end of the third finger of the hand on the thigh, and the participant will be asked to perform lateral flexion. The point where the distal of the third finger comes from is marked again. The distance between the two points is cm. will be recorded in terms. A higher value is associated with good flexibility.

Time frame: Change from Baseline Trunk Lateral Flexion Measure at 12 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupFlexibility Change With Trunk Lateral Flexion Measurebaseline12.95 centimeterStandard Deviation 3.31
Blue Prescription GroupFlexibility Change With Trunk Lateral Flexion Measureat the end of the 12 weeks17.47 centimeterStandard Deviation 3.29
Video Based Home Exercise GroupFlexibility Change With Trunk Lateral Flexion Measurebaseline13.68 centimeterStandard Deviation 4.19
Video Based Home Exercise GroupFlexibility Change With Trunk Lateral Flexion Measureat the end of the 12 weeks17.15 centimeterStandard Deviation 4.22
Supervised Exercise GroupFlexibility Change With Trunk Lateral Flexion Measurebaseline12.61 centimeterStandard Deviation 3.5
Supervised Exercise GroupFlexibility Change With Trunk Lateral Flexion Measureat the end of the 12 weeks18.89 centimeterStandard Deviation 2.91
p-value: 0.928ANCOVA
Secondary

Height

It will be measured with a stadiometer. Head, shoulders, back, hips, calves and heels will touch the stadiometer, stand upright with feet shoulder-width apart, slide of height meter will be pulled down.

Time frame: In the beginning of the intervention

ArmMeasureValue (MEAN)Dispersion
Blue Prescription GroupHeight1.57 meterStandard Deviation 0.06
Video Based Home Exercise GroupHeight1.58 meterStandard Deviation 0.05
Supervised Exercise GroupHeight1.59 meterStandard Deviation 0.05
p-value: 0.631ANCOVA
Secondary

Hip Circumference

Measured at the widest point of the Gluteus Maximus muscle in the anatomical position

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupHip Circumferencebaseline120.58 centimeterStandard Deviation 12.13
Blue Prescription GroupHip Circumferenceat the end of the 12 weeks117.84 centimeterStandard Deviation 11.33
Video Based Home Exercise GroupHip Circumferencebaseline113.60 centimeterStandard Deviation 7.96
Video Based Home Exercise GroupHip Circumferenceat the end of the 12 weeks111.90 centimeterStandard Deviation 7.97
Supervised Exercise GroupHip Circumferenceat the end of the 12 weeks112.17 centimeterStandard Deviation 7.83
Supervised Exercise GroupHip Circumferencebaseline116.72 centimeterStandard Deviation 8.72
p-value: 0.979ANCOVA
Secondary

Life Quality

The Diabetes Quality of Life (DQoL) Questionnaire consists of 46 items divided into four subscales: Satisfaction (15 items), Impact (20 items), Worry - Social/Vocational (7 items), and Worry - Diabetes-Related (4 items). Each item is rated on a 5-point Likert scale ranging from 1 to 5. Depending on the item, higher scores may indicate either greater dissatisfaction, greater impact, or higher worry. Subscale scores are calculated by summing item responses within each subscale. The total score is the sum of all items and ranges from 46 to 230. Higher total scores indicate a lower diabetes-related quality of life.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupLife Qualitybaseline3.57 units on a scaleStandard Deviation 0.58
Blue Prescription GroupLife Qualityat the end of the 12 weeks4.31 units on a scaleStandard Deviation 0.33
Video Based Home Exercise GroupLife Qualitybaseline3.61 units on a scaleStandard Deviation 0.51
Video Based Home Exercise GroupLife Qualityat the end of the 12 weeks4.29 units on a scaleStandard Deviation 0.3
Supervised Exercise GroupLife Qualitybaseline3.61 units on a scaleStandard Deviation 0.45
Supervised Exercise GroupLife Qualityat the end of the 12 weeks4.60 units on a scaleStandard Deviation 0.24
p-value: 0.558Kruskal-Wallis
Secondary

Neck Circumference

In the anatomical position, the tape measure is measured just below the thyroid cartilage.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupNeck Circumferencebaseline38.13 centimeterStandard Deviation 2.8
Blue Prescription GroupNeck Circumferenceat the end of the 12 weeks37.05 centimeterStandard Deviation 2.46
Video Based Home Exercise GroupNeck Circumferencebaseline38.05 centimeterStandard Deviation 3.02
Video Based Home Exercise GroupNeck Circumferenceat the end of the 12 weeks36.95 centimeterStandard Deviation 2.82
Supervised Exercise GroupNeck Circumferencebaseline38.53 centimeterStandard Deviation 2.84
Supervised Exercise GroupNeck Circumferenceat the end of the 12 weeks36.83 centimeterStandard Deviation 2.15
p-value: 0.979ANCOVA
Secondary

Waist Circumference

It is measured at the thinnest point between the lowest rib and anterior superior to the processus spina ilica in the anatomical position.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupWaist Circumferencebaseline104.42 centimeterStandard Deviation 14.45
Blue Prescription GroupWaist Circumferenceat the end of the 12 weeks100.16 centimeterStandard Deviation 13
Video Based Home Exercise GroupWaist Circumferencebaseline103.10 centimeterStandard Deviation 12.54
Video Based Home Exercise GroupWaist Circumferenceat the end of the 12 weeks98.60 centimeterStandard Deviation 12.65
Supervised Exercise GroupWaist Circumferencebaseline109.56 centimeterStandard Deviation 10.26
Supervised Exercise GroupWaist Circumferenceat the end of the 12 weeks102.78 centimeterStandard Deviation 8.02
p-value: 0.377ANCOVA
Secondary

Weight

It will be measured with a standard weighing instrument.

Time frame: In the beginning of the intervention and at the end of the exercise program (12 weeks).

ArmMeasureGroupValue (MEAN)Dispersion
Blue Prescription GroupWeightbaseline88.55 kgStandard Deviation 12.81
Blue Prescription GroupWeightat the end of the 12 weeks84.69 kgStandard Deviation 10.86
Video Based Home Exercise GroupWeightat the end of the 12 weeks77.96 kgStandard Deviation 11.07
Video Based Home Exercise GroupWeightbaseline79.87 kgStandard Deviation 11.65
Supervised Exercise GroupWeightat the end of the 12 weeks81.40 kgStandard Deviation 11.82
Supervised Exercise GroupWeightbaseline87.93 kgStandard Deviation 13.14
p-value: 0.056ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026